Medco, Mayo to Study Pharmacoeconomics of Genetically Testing Warfarin Patients | GenomeWeb
NEW YORK (GenomeWeb News) — Pharmacy benefits management company Medco and Mayo Collaborative Services plan to study whether using genetic tests can cut costs and improve care for patients taking the blood-thinner warfarin, Medco today.
 
Medco said it will work with Mayo to evaluate test data from more than 1,000 subjects from the roughly 200,000 individuals Medco tracks every year who are new to warfarin treatment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.